Critical Approach to Hypothyroid Patients With Persistent Symptoms

Area of Science:

• Endocrinology
• Thyroidology

Background:

• Levothyroxine (LT4) is the standard treatment for hypothyroidism, aiming for biochemical and clinical euthyroidism.
• Approximately 15% of patients on LT4 experience residual symptoms, leading to dissatisfaction and potential cardiovascular risks.
• Genetic factors and altered thyroid hormone metabolism contribute to persistent symptoms in some LT4-treated individuals.

Purpose of the Study:

• To evaluate the controversial benefits of combination therapy (LT4 plus liothyronine) for hypothyroidism.
• To provide a counterpoint to recent consensus documents on hypothyroidism treatment.

Main Methods:

• Review of existing literature, including randomized clinical trials and meta-analyses.
• Analysis of prescribing patterns and patient preferences for combination therapy.

Main Results:

• Meta-analyses indicate a preference for combination therapy in 46.2% of patients.
• Recent randomized trials have not shown clear benefits, but had limitations affecting generalizability.
• Guidelines from the American Thyroid Association (ATA) and European Thyroid Association (ETA) acknowledge LT4 limitations.

Conclusions:

• The optimal treatment for hypothyroidism remains debated, with ongoing discussion regarding combination therapy.
• Further research with robust study designs is needed to clarify the role of combination therapy.
• Physician prescribing patterns suggest increasing use of combination therapy despite inconclusive trial results.